Electrophysiology

The cardiac subspecialty of electrophysiology (EP) diagnoses and treats arrhythmias. This includes use of pacemakers to treat bradycardia, implantable cardioverter defibrillators (ICD) for tachycardia, heart failure and patients at risk of sudden cardiac arrest, and cardiac ablation treatments to treat heart rhythm disorders.

RSS icon
Biosense Webster gained CE mark approval for its Varipulse pulsed field ablation (PFA) system in Europe

Biosense Webster takes key step toward FDA approval for Varipulse PFA system

The company already received CE mark approval for its new PFA offering and hopes it will soon be approved for sale in the United States.

Going green in the cath lab makes economic sense

New research explored the potential savings of turning off angiography systems at night and on weekends.

Hoping to improve care for these patients, Hermann et al. turned to the ŌNŌ retrieval system, a catheter-delivered device cleared by the U.S. Food and Drug Administration in 2022. The device was developed by Ōnōcor, a U.S. healthcare startup with roots in the Penn Center for Innovation.

Cardiologists are first in world to remove unstable Watchman devices with FDA-cleared retrieval system

A team of specialists in Houston made history, using the new-look device to treat three patients over the age of 80. The group shared its experience in JACC: Clinical Electrophysiology.

Thumbnail

Heart issues more common in adults who drink soda, other sweetened beverages

Diet sodas made with artificial sweeteners are associated with an even higher risk of issues than sugar-sweetened sodas.

Thumbnail

Permanent pacemaker implantation after TAVR increases healthcare costs by $24,000 per patient

Researchers say their new analysis, based on five years of U.S. data, highlights just how important it is to keep post-TAVR PPMI rates to a minimum. 

Biosense Webster gained CE mark approval for its Varipulse pulsed field ablation (PFA) system in Europe

Biosense Webster gains CE mark approval for new PFA system

The news represents yet another big regulatory approval for PFA technology in 2024. Could FDA approval be next for Biosense Webster?

Biosense Webster, part of Johnson & Johnson MedTech, shared updated data on its Varipulse pulsed field ablation (PFA) system at AF Symposium 2024 in Boston,

Biosense Webster funding new PFA research

The VIRTUE and POLARIS studies are both focused on evaluating how the Varipulse PFA Platform performs in a variety of clinical scenarios. 

Thumbnail

Former NBA champion, Survivor contestant now fighting for his life as he waits for a heart transplant

Scot Pollard has a long family history of heart disease, and he’s been on a watch list for several years now due to his size. He's been in and out of hospitals for more than three years due to an ongoing fight with cardiomyopathy. 

Displaying 89 - 96 of 311
Design by Adaptive Theme